Banco de Sabadell S.A bought a new position in shares of Gilead Sciences (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 93,341 shares of the biopharmaceutical company’s stock, valued at approximately $6,686,000. Gilead Sciences comprises approximately 0.9% of Banco de Sabadell S.A’s investment portfolio, making the stock its 27th biggest position.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Macquarie Group Ltd. raised its holdings in Gilead Sciences by 26.6% in the 3rd quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after buying an additional 100,741 shares during the period. Parnassus Investments CA increased its stake in Gilead Sciences by 2.5% during the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock worth $1,372,604,000 after purchasing an additional 464,609 shares during the period. Vicus Capital increased its stake in Gilead Sciences by 31.5% during the third quarter. Vicus Capital now owns 11,496 shares of the biopharmaceutical company’s stock worth $931,000 after purchasing an additional 2,751 shares during the period. Sandy Spring Bank increased its stake in Gilead Sciences by 5.2% during the third quarter. Sandy Spring Bank now owns 43,234 shares of the biopharmaceutical company’s stock worth $3,503,000 after purchasing an additional 2,146 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in Gilead Sciences by 5.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 4,959,388 shares of the biopharmaceutical company’s stock worth $401,810,000 after purchasing an additional 252,556 shares during the period. 78.40% of the stock is currently owned by institutional investors.
A number of analysts have issued reports on the stock. Citigroup upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and cut their price target for the stock from $88.80 to $76.00 in a research note on Tuesday, January 30th. Vetr lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 price target on the stock. in a research note on Monday, January 29th. Morgan Stanley cut their price target on shares of Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 7th. Bank of America boosted their price objective on Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 7th. Finally, BMO Capital Markets boosted their price objective on Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a research report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $88.65.
Shares of GILD opened at $72.72 on Wednesday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. The company has a market capitalization of $96,093.74, a P/E ratio of 8.50, a price-to-earnings-growth ratio of -1.67 and a beta of 1.18. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same period in the prior year, the company posted $2.70 earnings per share. sell-side analysts predict that Gilead Sciences will post 6.32 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Investors of record on Friday, March 16th were issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.14%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend was Thursday, March 15th. Gilead Sciences’s dividend payout ratio is 26.64%.
TRADEMARK VIOLATION WARNING: “Banco de Sabadell S.A Takes $6.69 Million Position in Gilead Sciences (GILD)” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://stocknewstimes.com/2018/04/25/banco-de-sabadell-s-a-takes-6-69-million-position-in-gilead-sciences-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.